期刊文献+

恶性肿瘤合并深静脉血栓形成50例临床分析 被引量:17

Malignant tumor combined with deep vein thrombosis of 50 cases
暂未订购
导出
摘要 目的探讨恶性肿瘤并发深静脉血栓形成的原因、预防、诊断、治疗及预防再复发的方法。方法回顾分析2009年7月至2010年7月收治的50例恶性肿瘤并发深静脉血栓形成患者的临床资料,并总结肿瘤类型与深静脉血栓形成发病的密切程度。结果本组患者中乳腺癌(16%)最多,其次为宫颈癌(14%)、胰腺癌(10%)、肺癌(10%)。血栓类型以腓肠肌静脉丛血栓最多。所有患者经彩色多普勒超声检查及D-二聚体明确诊断后,予以溶栓、抗凝、祛聚等治疗,32例(64%)经1个疗程治疗后临床症状好转,6例经2个疗程治疗后好转,2例因肿瘤晚期多脏器功能衰竭死亡,10例因急于手术或化疗未正规治疗。出院3个月内复发8例(包括死亡2例),复发率16%。结论恶性肿瘤易合并深静脉血栓形成,尤其以术后患者多见。治疗以抗凝为主,多可缓解临床症状,但复发率较高。长期口服华法林及静脉压力治疗可以降低复发率。 Objective To discuss the causes, prevention, diagnosis and treatment of malignant tumor combined with deep vein thrombosis. Methods From July 2009 to July 2010, 50 cases of malignant tumor com- bined with deep vein thrombosis were retrospectively analyzed. Results In 50 cases, 16% was breast cancer, 14% was cervical cancer, 10% was pancreatic cancer and 10% was lung cancer. The largest proportion of thrombosis type was gastrocnemius venous plexus thrombosis. All cases were diagnosed by color Doppler ultra- sound and D-dimer, and used thrombolysis and anticoagulation to treat. 38 cases symptoms improved, 2 cases with advanced cancer died of multiple organ failure and 8 cases recurred within 3 months. Conclusions Ma- lignant tumor combined with deep vein thrombosis usually occurs in postoperative patients. Anticoagulant can re- lieve symptoms, but the recurrence rate is high, and long-term oral warfarin and venous pressure treatment can reduce the recurrence rate.
出处 《中国肿瘤外科杂志》 CAS 2011年第1期23-25,共3页 Chinese Journal of Surgical Oncology
关键词 深静脉血栓形成 腓肠肌静脉丛血栓 恶性肿瘤 低分子肝素 华法林 尿激酶 腔静脉滤器 deep vein thrombosis gastrocnemius venous plexus thrombosis malignant tumor low molecular weight heparin warfarin urokinase vena cavafiher
  • 相关文献

参考文献10

二级参考文献52

  • 1陈翠菊,杨镛,周兴立,段丽红,尹存平,郭曙光,方伟,张鹏.下肢深静脉血栓形成治疗新认识[J].中华外科杂志,2005,43(7):420-422. 被引量:52
  • 2Bick RL. Cancer-associated thrombosis[J]. N Eng J Med, 2003, 349(2): 109-111.
  • 3Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation[J]. Oncologist, 1999, 4(6): 443--449.
  • 4Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis[]]. AmJ Health Syst Pharm, 2005, 62(22 Suppl 5): s4--s6.
  • 5Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data[J]. Medicine, 1999, 78(5): 285-291.
  • 6Burris HA. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care[J]? Semin Oncol, 2006, 33(2 Suppl 4):S3-S16; quiz S41-S42.
  • 7BaronJA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer[J]. Lancet, 1998, 351(9109): 1077-1080.
  • 8Sorensen HT, Mellemkjaer L, Steffensen FH, et al.. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism[J]. N EnglJ Med, 1998, 338 (17): 1169-1173.
  • 9GomuzJ, Pearson SD, Greager MA, et al. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis[J]. Ann Intern Med, 1996, 125 (10): 785-793.
  • 10Murchison JT, Wyfie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study[]]. BrJ Cancer, 2004, 91(1): 92-95.

共引文献78

同被引文献116

引证文献17

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部